{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:06:28Z","timestamp":1781219188162,"version":"3.54.1"},"reference-count":75,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"ESTEVE Pharmaceuticals S.A."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2024,3,3]]},"DOI":"10.1080\/03007995.2023.2276118","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T13:18:22Z","timestamp":1704979102000},"page":"455-468","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Co-crystal of tramadol\u2013celecoxib (CTC) for acute moderate-to-severe pain"],"prefix":"10.1080","volume":"40","author":[{"given":"Richard","family":"Langford","sequence":"first","affiliation":[{"name":"The London Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Margarit","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Alicante, Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelaida","family":"Morte","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Cebrecos","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Sust","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Ortiz","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Gim\u00e9nez-Arnau","sequence":"additional","affiliation":[{"name":"ESTEVE Pharmaceuticals S.A., Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"de Leon-Casasola","sequence":"additional","affiliation":[{"name":"University of Buffalo\/Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-770"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acpain.2004.08.002"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000081722.09164.D5"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1213\/01.ANE.0000068822.10113.9E"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2019.1612557"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.12.005"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S137992"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-024441"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093289"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.860019"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2010.00983.x"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68700-X"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjae.2021.11.008"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S208082"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11916-017-0607-y"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000513527.71934.73"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e31823c1030"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anclin.2017.01.018"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2015.12.008"},{"key":"e_1_3_6_21_1","unstructured":"European Society for Emergency Medicine (EUSEM). Guidelines for the management of acute pain in emergency situations. 2020 [cited 2023 May 3]. https:\/\/www.eusem.org\/images\/EUSEM_EPI_GUIDELINES_MARCH_2020.pdf."},{"key":"e_1_3_6_22_1","unstructured":"Schug SA Palmer GM Scott DA et\u00a0al. Acute pain management: scientific evidence (5th ed.). Melbourne: ANZCA & FPM; 2020 [cited 2023 May 30]. https:\/\/www.anzca.edu.au\/resources\/college-publications\/acute-pain-management\/apmse5.pdf."},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11477"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.6b01848"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.cgd.9b00008"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13395"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13428"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.04.002"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13136"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.2021"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02744-2"},{"key":"e_1_3_6_32_1","unstructured":"Kowa Pharmaceuticals America Inc. Selgentis: US prescribing information. 2021 [cited 2023 June 26]. https:\/\/www.kowapharma.com\/documents\/SEGLENTIS_Prescribing_Information.pdf."},{"key":"e_1_3_6_33_1","unstructured":"ESTEVE. ESTEVE announces FDA approval of a novel co-crystal form of celecoxib and tramadol for the management of acute pain [internet]. 2021 [cited 2023 May 3]. https:\/\/www.esteve.com\/uk\/news\/esteve-announces-fda-approval-of-a-novel-co-crystal-form-of-celecoxib-and-tramadol-for-the-management-of-acute-pain."},{"key":"e_1_3_6_34_1","unstructured":"Centro de Informaci\u00f3n de Medicamentos (CIMA). Velyntra 44 mg\/56 mg film-coated tablets. Registration 89051 [internet]. 2023 [cited 2023 Nov 13]. https:\/\/cima.aemps.es\/cima\/publico\/detalle.html?nregistro=89051"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9394-1"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-018-0479-7"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-020-01864-0"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.942281"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2016.0063"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2020.1735356"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1039\/c6cc02943d"},{"key":"e_1_3_6_42_1","unstructured":"Novartis Pharmaceuticals Corp. Diovan: US prescribing information. 2017 [cited 2023 July 26]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021283s50lbl.pdf."},{"key":"e_1_3_6_43_1","unstructured":"Novartis Pharmaceuticals Corp. Diovan: summary of product characteristics. 2020 [cited 2023 31 July]. https:\/\/www.hpra.ie\/img\/uploaded\/swedocuments\/Licence_PA0896-009-001_30062020113701.pdf."},{"key":"e_1_3_6_44_1","unstructured":"Novartis Pharmaceuticals Corp. Entresto: US prescribing information. 2021 [cited 2023 July 26]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/207620s018lbl.pdf."},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.877237"},{"issue":"6","key":"e_1_3_6_46_1","first-page":"330","article-title":"Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure","volume":"8","author":"Fala L.","year":"2015","unstructured":"Fala L. Entresto (sacubitril\/valsartan): first-in-class angiotensin receptor neprilysin inhibitor FDA approved for patients with heart failure. Am Health Drug Benefits. 2015;8(6):330\u2013334.","journal-title":"Am Health Drug Benefits"},{"key":"e_1_3_6_47_1","unstructured":"European Medicines Agency. Entresto: EMA authorisation. 2015 [cited 2023 July 31]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/entresto#authorisation-details-section."},{"key":"e_1_3_6_48_1","unstructured":"WHO Collaboration Centre for Drug Statistics Methodology. ATC index [internet]. 2023 [cited 2023 June 12]. https:\/\/www.whocc.no\/atc_ddd_index\/."},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000001683"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2018.06.022"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000057"},{"key":"e_1_3_6_52_1","volume-title":"Medical genetics summaries","author":"Dean L","year":"2012","unstructured":"Dean L, Kane M. Tramadol therapy and CYP2D6 genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012."},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2000.00209.x"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2015.09.005"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0491-9"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0672-y"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-018-0235-y"},{"key":"e_1_3_6_58_1","unstructured":"Viatris Upjohn UK Limited. Celebrex 100mg capsule: summary of product characteristics [internet]. 2022 [cited 2023 May 4]. https:\/\/www.medicines.org.uk\/emc\/product\/5533\/smpc#gref."},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/papr.13136"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2013.876979"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/00913847.2015.1025029"},{"key":"e_1_3_6_62_1","unstructured":"ESTEVE. CTC (44\u2009mg tramadol and 56\u2009mg celecoxib tablet) co-crystal of tramadol and celecoxib. Joint Meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee [internet]. 2020 [cited 2023 13 July]. https:\/\/pink.pharmaintelligence.informa.com\/-\/media\/supporting-documents\/pink-sheet\/2020\/01\/tramadol_celecoxib_ac_esteve_brfg.pdf?rev=68b8c837b6c44ce5b1951e6c600cf9f1&hash=16D0364A7A107A7B47F2659ABA1152F4."},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/1757-1146-3-21"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2013.09.002"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.119156"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050405"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611593"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2021.644391"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S75160"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200603000-00020"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050330"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002254"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2020.1734456"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.10734"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2276118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T05:57:55Z","timestamp":1729663075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2276118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,3]]}},"alternative-id":["10.1080\/03007995.2023.2276118"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2276118","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}